Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: Does quality of life matter?

Journal of Clinical Oncology

Volumn 17, Issue 6, 1999, Pages 1672-1679

  Bernhard, Jürg ^a   Thurlimann B ^a   Hsu Schmitz, S F ^a   Castiglione Gertsch, M ^a   Cavalli, F ^a   Morant, R ^a   Fey, M F ^a   Bonnefoi, H ^a   Goldhirsch, A ^a   Hurny C ^a  

^a Ospedale Civico Lugano   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FORMESTANE; MEGESTROL ACETATE;

ADULT; AGED; APPETITE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPING BEHAVIOR; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT FAILURE; VERTIGO; WELLBEING;

EID: 0344299103     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.6.1672     Document Type: Article

References (16)

1. Howell A, Mackintosh J, Jones M, et al: The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 24:1567-1572, 1988
2. Robertson JFR, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25:469-475, 1989
3. Jonat W, Howell A, Blomqvist C, et al: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A:404-412, 1996
4. Thürlimann B, Castiglione M, Hsu Schmitz SF, et al: Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 33:1017-1024, 1997
5. Robertson JFR, Willsher PC, Cheung KL, et al: The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774-1779, 1997
6. Bernhard J, Castiglione-Gertsch M, Hsu Schmitz S-F, et al: Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: Formestane versus megestrol acetate as second-line hormonal treatment. Eur J Cancer (in press)
7. Coates A, Fisher Dillenbeck CF, McNeil DR, et al: On the receiving end: II. Linear analogue self-assessment (LASA) in evaluation of aspects of the quality of life of cancer patients receiving chemotherapy. Eur J Cancer Clin Oncol 19:1633-1637, 1983
8. Coates A, Glasziou P, McNeil D: On the receiving end: III. Measurement of quality of life during cancer chemotherapy. Ann Oncol 1:213-217, 1990
9. Hürny C, Bernhard J, Bacchi M, et al: The Perceived Adjustment to Chronic Illness Scale (PACIS): A global indicator of coping for operable breast cancer patients in clinical trials - Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG). Support Care Cancer 1:200-208, 1993
10. Bernhard J, Hürny C, Coates AS, et al: Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach - The International Breast Cancer Study Group. Ann Oncol 8:825-835, 1997
11. Coates A, Gebski V, Signorini D, et al: Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. J Clin Oncol 10:1833-1838, 1992
12. Baum M, Priestman T, West RR, et al: A comparison of subjective responses in a trial comparing endocrine with cytotoxic treatment in advanced carcinoma of the breast. Eur J Cancer 16:223-226, 1980 (suppl)
13. Coates A, Gebski V, Bishop JF, et al: Improving the quality of life during chemotherapy for advanced breast cancer: A comparison of intermittent and continuous treatment strategies. N Engl J Med 317:1490-1495, 1987
14. Tandon PK: Application of global statistics in analyzing quality of life data. Stat Med 9:819-827, 1990
15. Hürny C, Bernhard J, Coates AS, et al: Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer: International Breast Cancer Study Group. Lancet 347:1279-1284, 1996
16. Bernhard J, Cella DF, Coates AS, et al: Missing quality of life data in cancer clinical trials: Serious problems and challenges. Stat Med 17:517-532, 1998